Showing results (91-100 of 137) with videos related to

Sort By:
Pageof 14
Prostate Cancer and Prostatic Diseases|November 16, 2018
Immediate treatment vs. active-surveillance in very-low-risk prostate cancer: the role of patient-, tumour-, and hospital-related factorsHanneke Jansen, Inge M van Oort, George van Andel, et al.
International Journal of Cancer|September 23, 2020
Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancerPeter H J Slootbeek, Marleen L Duizer, Maarten J van der Doelen, et al.
Radiology|May 21, 2024
Multiparametric MRI and 18F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate CancerBastiaan M Privé, Bas Israël, Marcel J R Janssen, et al.
Frontiers in Nuclear Medicine|October 2, 2024
An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate CancerBastiaan M Privé, Constantijn H J Muselaers, Inge M van Oort, et al.
Oncoimmunology|July 8, 2022
Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtypeSandra van Wilpe, Donjetë Simnica, Peter Slootbeek, et al.
Prostate Cancer and Prostatic Diseases|October 12, 2022
Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registryGijs P A van den Bergh, Malou C P Kuppen, Hans M Westgeest, et al.
Oncology|August 22, 2016
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate CancerSushil K Badrising, Vincent van der Noort, Paul Hamberg, et al.
Prostate Cancer and Prostatic Diseases|July 8, 2022
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapyMaarten J van der Doelen, Irma M Oving, Dirk N J Wyndaele, et al.
The Prostate|September 23, 2015
Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relationSushil K Badrising, Vincent van der Noort, Alfons J M van den Eertwegh, et al.
Prostate Cancer and Prostatic Diseases|May 4, 2021
Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve menRianne J Hendriks, Marloes M G van der Leest, Bas Israël, et al.
Pageof 14